Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends INDIA LIVE 2018


Chennai, India – Shanghai MicroPort Medical Group Co., Ltd. ("MicroPort®") recently attended the annual INDIA LIVE 2018 in India to display its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
During the meeting, a live case of Firehawk® was broadcasted to demonstrate its clinical performance. The operation was conducted by Dr. S.Mullasari Ajit of India-based hospital The Madras Medical Mission to treat a 57-year-old male patient with diabetes and unstable angina pectoris. He had been implanted a stent in the right coronary artery and was again admitted to hospital due to vascular restenosis. Dr. S.Mullasari Ajit predilated the lesion and successfully implanted a 3.5*18mm Firehawk® in the lesion. The postoperative OCT shows excellent outcome and the outstanding pushability and crossability of Firehawk® were highly recognized by physicians and experts in attendance.
During the meeting, several renowned cardiologists including Professor Upendra Kaul of Escorts Heart Institute and Dr. Anil Kumar of Aster Medicity Hospital visited MicroPort® booth and had in-depth discussion regarding the clinical performance of MicroPort® products with Dr. Linda Lin, MicroPort® First Vice President of International Business.
India has the third largest amount of PCI cases in the world, and the market has been experiencing rapid development in recent years. During this meeting, MicroPort® took the opportunity to enhance communications with local experts and demonstrated its strength and growth potential to them. As Firehawk® and Firefighter™ PTCA Balloon Catheter ("Firefighter™") have been gaining higher recognition among local patients and physicians, MicroPort® is enlarging its influence and market share in the India market. In the future, MicroPort® will further expand the India market to provide ideal medical solutions for local patients suffering from cardiovascular diseases.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Vertebral Artery Rapamycin Target Eluting Stent System Granted CFDA Green-Path
[Next]:MicroPort® Orthopedics Attends CHS 2018